Containing GS-441524, NeoFipronis® (Pronidesivir) provides convenient oral administration, batch traceability, and quality-control support for cats with feline infectious peritonitis.
Vientiane, Laos — March 2, 2026 — NeoFipronis® (Pronidesivir) has officially launched as an oral GS-441524 veterinary tablet for cats with feline infectious peritonitis, commonly known as FIP.
NeoFipronis® (Pronidesivir) has been officially registered in Laos and is now available through authorized channels. The launch marks an important step toward providing a more standardized, traceable, and quality-controlled oral GS-441524 veterinary product for FIP treatment.
During FIP treatment, long-term, regular, and consistent medication management is essential. Traditional injectable options may cause pain, stress, and handling challenges for cats, while also increasing the difficulty of daily administration for cat owners. NeoFipronis® (Pronidesivir) is formulated as an oral tablet to help improve dosing convenience during long-term treatment.
NeoFipronis® is the brand name of Pronidesivir, while GS-441524 is its active ingredient. The product is manufactured under controlled quality standards and supports batch traceability and product verification, helping reduce quality and safety risks associated with non-standard or unauthorized products.
NeoFipronis® (Pronidesivir) focuses not only on the product itself, but also on information transparency and standardized use throughout the FIP treatment process. Pronidesivir.com, the official website of NeoFipronis® (Pronidesivir), will continue to provide product information, frequently asked questions, usage guidance, batch inquiry, and authorized-channel information to help cat owners better understand the product.
The launch of NeoFipronis® (Pronidesivir) represents an important step in promoting the standardization of FIP treatment products. The brand will continue to build long-term support around product quality, veterinary guidance, reliable information, and user assistance.